|  |  |  |  | Number of subjects | RR (95% CI) | ||||
---|---|---|---|---|---|---|---|---|---|---|
Grade | Study | Age (years) | Follow-up (years) | Definition | DM | No DM | All dementia | VaD | AD + VaD | AD |
B1 | Yoshitake et al. 1995 [11]; Hisayama 1985 to 1992 (n = 828) | >65 | 7 | Hx | 70 | 756 | Â | 2.8 (2.6, 3.0) a | Â | 2.2 (0.97, 4.9)a |
B1 | Ott et al. 1999 [23]; Rotterdam 1990 to 1994 (n = 6,370) | >55 | 2.1 | Hx: Glu >11 mmol/L | 692 | 5,678 | 1.9 (1.3, 2.8)b | 2.0 (0.7, 5.6)b | 3.0 (1.0, 9.3) b | 1.8 (1.1, 3.0) b |
B1 | Luchsinger et al. 2001 [49]; WHICAP 1992 to 1997 (n = 1,262) | ≥65, mean 75.6 (SD 5.9) | 4.3 | Hx | 255 | 1,007 |  | 3.4 (1.7, 6.9) c |  | 1.3 (0.8, 1.9)d |
B1 | MacKnight et al. 2002 [26]; CSHA (n = 5,574) | ≥65 | 4-6 | Hx: Glu >11.1 mmol/L | 503 | 5,071 | 1.26 (0.9, 1.7)e | 2.03 (1.15, 3.5) e |  | 1.3 (0.83, 2.1)e |
B1 | Peila et al. 2002 [15]; HAAS 1991 to 1996 (n = 2,574) | 72-93 | 2.9 | Hx DM: FBS >120 mg/dl | 900 | 1,674 | 1.5 (1.0, 2.2)f | 2.3 (1.1, 5.0) f | 1.8 (1.1, 2.9) f | 1.6 (0.9, 3.0)f |
B1 | Cheng et al. 2011 [25]; WHICAP 1999 to 2001 (n = 1,488) | >65 | Â | Hx | Â | Â | 1.7 (1.4, 2.90)g | 1.6 (1.0, 2.6) g | 1.3 (0.8, 2.2)g | Â |
B2 | Arvanitakis et al. 2004 [17]; Religious Orders Study (n = 990) | 75 | 5.5 | Hx | 127 | 697 | Â | Â | Â | 1.6 (1.1, 2.5) h |
B2 | Ahtilouoto et al. 2010 [16]; Vantaa 85+ (n = 588) | >85 | Â | Hx | 87 | 268 | 2.09 (1.34, 3.25) No APOE4: 1.68 (0.99, 2.83) With APOE4: 3.80 (1.69, 8.53) | Â | Â | Â |